We would love to hear your thoughts about our site and services, please take our survey here.
Nice delayed kipper just landed - printed in the median - grey trade
25-Mar-24 16:37:00 1.704 800,000 Unknown* 1.695 1.75 13.63k O
Low volume 3.5 million -
Yet showing blue +1% - all manoeuvres within the spread
Vwap 1.705
This moot character who has sprung up coincidentally the same time as a short was opened at 1.6 , unfortunately the stock has gone north since .
Perhaps be a sleeper account as not posted for a yr & straight on here , after bombarding ciz .
Some crazy cooters with crazy agenda on these forums & stand out like a Mandrills backside in heat .
Orph & all - Morning
Unfortunately these forums are awash with toxic traders reeking of agenda ,
desperate to be ‘ Wolf of Wall St ‘ however only managed ‘ Mudskipper of Bog St ‘
The figures don’t lie & neither does company news ,
huge risk to open a short at sub current price , imo & hope they get their backsides napalmed
Fetch the Sunday bacon banjos
Morning all invested
Shorters can kiss my leathery ass 👍
Stock on loan / shorts
Currently 5.07 million - value 87k
( a 3.25 million short was opened on Friday 15th /mon 18th at that stage price was 1.6 &- obviously wanting the price lower ,)
- the week previous a 1.75 million short was opened & still open .hence 5 million total
( ties in with recent negativity on this & other forums , connected ? i think so as been on these boards for yrs & seen all the toxic trading patterns
, unfortunately the stock is going the wrong direction for the bozos this week closing at 1.72
To much buying demand , let’s hope a positive RNS drops Monday & napalms their backsides .
Cost to borrow 14
No flagged shorts
Volume Friday - 6.2 million
Average 3 month vol - 15 million
Trading - investing .com
RSI - has jumped to 54
indicators have moved positive to strong buy with Fridays close above 1.71
All above for info purposes & none will matter with a positive CAR T update with potential pharma deal , current price will be Broadsided .imo
Especially re reading recent RNS & watch latest interview .
Fetch the Full English with all the trimmings including black pudding
6. Cartherics to Try CAR-NK Cell Therapy Targeted at Tissue Factor Via Agreement With Ohio State University
Cartherics has executed an option agreement for research using intellectual property from The Ohio State University that covers the use of CAR natural killer (NK) cell therapy to target tissue factor (TF), a coagulation factor expressed in some tumor tissues and tumor blood vessels.
7. Hemogenyx Garners $4.2 Million Via Placing Shares
The company will put the net proceeds from this move towards HEMO-CAR-T, its CAR-T therapy that has been cleared by the FDA for a phase 1 clinical trial in patients with acute myeloid leukemia. "This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T," Vladislav Sandler, PhD, the CEO and cofounder of Hemogenyx, said in a statement.
Let’s all invested hope some sort of pharma deal gets thrashed out via Prevail & Vlad
Around the Helix: Cell and Gene Therapy Company Updates – March 20, 2024
( Hemo on 2and page )
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive®'s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Have a cell and gene therapy news update you'd like to share with our editorial team? Tag us on social and use #AroundTheHelix!
1. FDA Approves Liso-Cel (Breyanzi) as First CAR-T for CLL, SLL
The FDA has approved Bristol Myers Squibb's chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi) for treating adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor, under the accelerated approval pathway.
2. ODAC Meeting: Cilta-Cel Gets Unanimous Vote, Ide-Cel Wins Majority Vote for Benefit-Risk Profile
The FDA's Oncologic Drugs Advisory Committee (ODAC) Meeting has unanimously voted (11 yes, 0 no, 0 abstain) in favor of ciltacabtagene autoleucel's (cilta-cel; Janssen, Legend Biotech) benefit-risk profile for patients with relapsed and lenalidomide-refractory multiple myeloma (MM) after at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
3. FDA Approves Orchard Therapeutics' Gene-Edited Cell Therapy Arsa-Cel for Metachromatic Leukodystrophy
The FDA has approved Orchard Therapeutics' gene-edited cell therapy atidarsagene autotemcel (arsa-cel, previously referred to as OTL-200 and now marketed in the US under the name Lenmeldy), for the treatment of children with presymptomatic late infantile, PS early juvenile, or early symptomatic early juvenile metachromatic leukodystrophy (MLD). Several days after the approval Orchard announced that the therapy will be priced at $4.25 million in the US.
4. Patients With Hemophilia Biding Their Time for Gene Therapy
Many patients with hemophilia A/B are content with their current treatment regimens and only a minority are currently eager to undergo gene therapy, presenting a challenge in attempting to establish best practices for informed consent with the treatment mode.
5. ImmPACT Bio Secures Grant to Bring CD19/CD20 Bispecific CAR-T to Lupus
ImmPACT Bio has received an $8 million grant from the California Institute for Regenerative Medicine that will help support clinical development of IMPT-514, an investigational CAR-T that is currently being evaluated in a phase 1b/2 clinical trial for the treatment of refractory lupus nephritis and systemic lupus erythematosus.
6. Cartherics to Try CAR-NK Cell Therapy Targeted at Tissue Factor Via Agreement With Ohio State University
Continues
MR I & all
Don’t give a monkeys if it’s a man , women or alien
It’s toxic & talks bo11ocks
I’ve posted every day for two weeks since having treatment & 8 of them were red , so factually he’s incorrect & irritating ,
He/she is a dipping trader who goads when the narrative doesn’t suit the trade , & the goading appears ,
‘ It springs up like a toxic blow up doll in the back of Del Boys van ‘
Pump & all
It’s relevant to anyone invested & just info .
Where as you & your pathetic comments backed up with silly emojis are completely irrelevant
You mentioned previously you have a partner , Jesus Christ I pity them listening to you on a daily basis , petty & toxic don’t cover it .
Another delayed 1 million kipper printed on the median - grey trade
Someone’s mopping up the stock …
22-Mar-24 13:49:25 1.70 1,000,000 Unknown* 1.695 1.725 17.00k O
Update on CAR T next week would suffice
She’s in Blue waters 1.7 + %
( only a nose however the cautious reversal is maintained)
1.72.5 ask 1.695 bid
1.71 paid
Vwap 1.69
Vol 4 million - thin - with a trust of volume imo this would fly after recent shenanigans
Let’s see where the stock is at in a month
Imo - never below 2 again & any whiff of a positive CAR T / CBR update & up she will go .
Potential upside from current levels is certainly worth adding imo
Hence another dry powder buy from myself to add to my low position .
22-Mar-24 08:42:42 1.689 87,664 Buy* 1.66 1.70 1,481 O
No good trying to buy when the whiff of next news lands & especially re reading recent RNS & listening to interview . Imo .
Let’s see what next month brings - Vlads certainly quiet at present busy turning those CAR T cogs with Prevail no doubt .
Morning all invested
Looks like stock re grouped at current levels & a second go at reversing north although cautious , bounced from 1.6 lows .
Stock price 1,69
Vwap 1.67
1.7 paid -
Increase in vol & she will rise ….
The deflated sails due to the recent placement are hopefully & slowly been re hoisted -
& when look beyond the placement & what Hemo has achieved & what’s now coming in not to distant future…
CAR T - Clinical & underpinned by Prevail .
CDX - cooking
CBR - - virus eradication & Brain delivery
& now plenty of cash in the Bank to get to clinical .
She will reverse north as fast as south when the next RNS drops imo & still sat under the placement price & well below prevails toss in .
In a nutshell,imo certainty worth adding at current levels which is exactly what I have done .
Let’s see what next month brings
Haywain & all
No worries dude , & agreed imo a bargain at current levels , sat under recent placement with millions in the bank & clinical with Prevail underpinning potential deals .
The placement spooked a few however if investors thought it was worth 3/4p then why not add at 1.7 , & as you say RNS ain’t far away imo .
Back on the grog next week 👍
Based on the recent RNS & stock potential especially from current over leathered levels imo
I’ve tossed some dry powder in .
21-Mar-24 15:06:03 1.675 236,908 Buy* 1.655 1.675 3,968
Let’s see we are after next RNS
JFTH & all
Certainly looks like AI bot has had a meltdown , like I say 200 of them , or is it the resident negheads coppering up & buying in 👍
These are only a small sample + a nice buy to follow
21-Mar-24 13:18:15 1.6722 500,000 Buy* 1.65 1.68 8,361 O
21-Mar-24 13:16:18 1.675 1 Buy* 1.655 1.675 0.02 A
21-Mar-24 13:16:18 1.675 1 Buy* 1.655 1.675 0.02 A
21-Mar-24 13:16:18 1.675 1 Buy* 1.655 1.675 0.02 A
21-Mar-24 13:16:18 1.675 1 Buy* 1.655 1.675 0.02 A
21-Mar-24 13:16:18 1.675 1 Buy* 1.655 1.675 0.02 A
21-Mar-24 13:16:18 1.675 1 Buy* 1.655 1.675 0.02 A
Nice if they were all 1 million buys 👍
Plenty feel like that dudes ,
However if a pharma deal was announced on clinical & the stock shot to 10p , many would then wish they had purchased more at the current level .
That’s the markets for you
Morning all
Had to look twice then as I thought I was hallucinating when blue was on the screen ..
Are we finally reversing north & staying north as had two attempts .
4 million vol
We all know what Hemo have achieved in recent months the Market & large investors just need to follow suit .
Clinical pharma deal will suffice for starters
JFTH & all
Its showing the short was opened last week , 1.75 million -30k & yes certainly a big risk in thin volume & at the current stock price & as I’ve noted & yourself likely connected to some of the recent negativity on forums .
unless of course it’s hedging to a larger long position certainly plenty of large delayed kippers being printed in recent sessions .
We can only speculate with the scrag ends of info we can rummage out
Bring on the clinical & get this beast back to 4+ p to start.